McDonnell Boehnen Hulbert & Berghoff LLP partner Kirsten Thomson is quoted in a November 17, 2017 MobiHealthNews article entitled, “In-Depth: How digital sensors could change the face of pharma.” Earlier this week, Proteus Digital Health and Otsuka Pharmaceuticals announced that Abilify MyCite, a new, sensor-enabled version of Otsuka’s drug for schizophrenia, had received FDA approval for mental health conditions including schizophrenia and bipolar disorder. view the article
